INTRODUCTION: Chagas disease is a major cause of cardiomyopathy and sudden death in our country. It has a high mortality when their patients develop New York Heart Association (NYHA) class IV. OBJECTIVE: The objective of this study is to analyze the clinical outcome of patients with Chagas' cardiomyopathy with congestive heart failure with optimized pharmacological therapy, undergoing cardiac resynchronization therapy. METHODS: Between January 2004 and February 2009, 72 patients with Chagas' cardiomyopathy in NYHA class III and IV underwent cardiac resynchronization therapy and were monitored to assess their clinical evolution. We used the t test or the Wilcoxon test to compare the same variable in two different times. A P value < 0.05 was established as statistically significant. RESULTS: The average clinical follow-up was 46.6 months (range 4-79 months). At the end of the evaluation, 87.4% of patients were in NYHA class I or II (P<0.001). There was response to therapy in 65.3% of patients (P<0.001), with an overall mortality of 34.7%. CONCLUSION: In patients with chronic Chagas cardiomyopathy undergoing cardiac resynchronization therapy, we found the following statistically significant changes: improvement in NYHA class and increase of left ventricle ejection fraction, a decrease of the systolic final diameter and systolic final left ventricle volume and improvement of patient survival.
INTRODUCTION:Chagas disease is a major cause of cardiomyopathy and sudden death in our country. It has a high mortality when their patients develop New York Heart Association (NYHA) class IV. OBJECTIVE: The objective of this study is to analyze the clinical outcome of patients with Chagas' cardiomyopathy with congestive heart failure with optimized pharmacological therapy, undergoing cardiac resynchronization therapy. METHODS: Between January 2004 and February 2009, 72 patients with Chagas' cardiomyopathy in NYHA class III and IV underwent cardiac resynchronization therapy and were monitored to assess their clinical evolution. We used the t test or the Wilcoxon test to compare the same variable in two different times. A P value < 0.05 was established as statistically significant. RESULTS: The average clinical follow-up was 46.6 months (range 4-79 months). At the end of the evaluation, 87.4% of patients were in NYHA class I or II (P<0.001). There was response to therapy in 65.3% of patients (P<0.001), with an overall mortality of 34.7%. CONCLUSION: In patients with chronic Chagas cardiomyopathy undergoing cardiac resynchronization therapy, we found the following statistically significant changes: improvement in NYHA class and increase of left ventricle ejection fraction, a decrease of the systolic final diameter and systolic final left ventricle volume and improvement of patient survival.
Authors: William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: Cheuk-Man Yu; Gabe B Bleeker; Jeffrey Wing-Hong Fung; Martin J Schalij; Qing Zhang; Ernst E van der Wall; Yat-Sun Chan; Shun-Ling Kong; Jeroen J Bax Journal: Circulation Date: 2005-09-06 Impact factor: 29.690
Authors: A Auricchio; C Stellbrink; M Block; S Sack; J Vogt; P Bakker; H Klein; A Kramer; J Ding; R Salo; B Tockman; T Pochet; J Spinelli Journal: Circulation Date: 1999-06-15 Impact factor: 29.690
Authors: S Cazeau; C Leclercq; T Lavergne; S Walker; C Varma; C Linde; S Garrigue; L Kappenberger; G A Haywood; M Santini; C Bailleul; J C Daubert Journal: N Engl J Med Date: 2001-03-22 Impact factor: 91.245
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Steven L Higgins; John D Hummel; Imran K Niazi; Michael C Giudici; Seth J Worley; Leslie A Saxon; John P Boehmer; Michael B Higginbotham; Teresa De Marco; Elyse Foster; Patrick G Yong Journal: J Am Coll Cardiol Date: 2003-10-15 Impact factor: 24.094
Authors: S Cazeau; P Ritter; S Bakdach; A Lazarus; M Limousin; L Henao; O Mundler; J C Daubert; J Mugica Journal: Pacing Clin Electrophysiol Date: 1994-11 Impact factor: 1.976
Authors: Marc Vanderheyden; Wilfried Mullens; Leen Delrue; Marc Goethals; Bernard de Bruyne; William Wijns; Peter Geelen; Sofie Verstreken; Francis Wellens; Jozef Bartunek Journal: J Am Coll Cardiol Date: 2008-01-15 Impact factor: 24.094
Authors: Jefferson Luis Vieira; Fábio Rocha Fernandes Távora; Maria Gyslane Vasconcelos Sobral; Glauber Gean Vasconcelos; Germana Porto Linhares Almeida; Juliana Rolim Fernandes; Laura Leite da Escóssia Marinho; Daniel Francisco de Mendonça Trompieri; João David De Souza Neto; Juan Alberto Cosquillo Mejia Journal: Curr Cardiol Rep Date: 2019-02-12 Impact factor: 3.955
Authors: Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro Journal: Expert Rev Cardiovasc Ther Date: 2015-10-23
Authors: Sindhu Chadalawada; Anis Rassi; Omar Samara; Anthony Monzon; Deepika Gudapati; Lilian Vargas Barahona; Peter Hyson; Stefan Sillau; Luisa Mestroni; Matthew Taylor; Maria da Consolação Vieira Moreira; Kristen DeSanto; Nelson I Agudelo Higuita; Carlos Franco-Paredes; Andrés F Henao-Martínez Journal: ESC Heart Fail Date: 2021-10-30